Drug Profile
Naboctate
Alternative Names: SP 325Latest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator HG Pars
- Class Antiglaucomas
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 06 Jul 1998 No-Development-Reported for Glaucoma in USA (IV)
- 06 Jul 1998 No-Development-Reported for Glaucoma in USA (PO)
- 06 Jul 1998 No-Development-Reported for Glaucoma in USA (Topical)